SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare’s arm enters into strategic equity partnership with Gate2Brain

03 Jun 2026 Evaluate

Shilpa Medicare’s wholly owned subsidiary-- Shilpa Biocare has entered into a strategic equity partnership with Gate2Brain, S.L. (Gate2Brain), a biotechnology company pioneering peptide-shuttle therapeutics for central nervous system (CNS) diseases. Under the terms of the agreement, Shilpa becomes a strategic shareholder of Gate2Brain and its dedicated CMC, manufacturing, and regulatory partner for G2B-002--Gate2Brain's lead program in brain cancer.

G2B-002 has been granted Orphan Drug Designation (ODD) by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), underscoring its potential in rare and aggressive pediatric and adult brain tumors. The candidate is designed to target diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM)-- two of the most lethal childhood brain cancers, with very limited treatment options today. G2B-002 delivers SN-38, a potent anticancer agent, across the blood-brain barrier (BBB) via Gate2Brain's proprietary MiniAp4 peptide shuttle.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications. 


Shilpa Medicare Share Price

536.75 10.65 (2.02%)
05-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.55
Dr. Reddys Lab 1277.80
Cipla 1400.70
Zydus Lifesciences 1088.90
Lupin 2268.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×